Study of AL58805 for advanced cancers
Part of Cancer clinical trials.
This trial is testing a new drug called AL58805 for people with advanced cancers that have not improved with standard treatments. The goal is to see if the drug is safe and can help shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced cancer (like lung, breast, colon, or others) that hasn't responded to standard treatments.
- You have a tumor that can be seen on a scan (measurable disease).
- Your blood counts, liver, and kidney function are within acceptable ranges.
- Your heart is healthy (no recent heart attack, no uncontrolled rhythm problems, and good pumping function).
- You are at least 18 years old, able to walk and take care of yourself (ECOG 0 or 1), and expected to live at least 12 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called CS23546 for people with advanced solid tumors or lymphoma that have not responded to other treatments. Researchers will check your tumor for certain markers (PD-L1 and MSI) to see if the drug might work for you.
This Phase 2 study tests whether ALK-targeted drugs can shrink or control advanced squamous cell cancer that has spread. You may be eligible if your tumor has an ALK gene rearrangement and you have not had prior cancer medicines for this stage.
This trial tests a new oral drug called AL8326 for people with advanced small cell lung cancer who have already tried at least two other treatments. The goal is to see if the drug can shrink tumors and help patients live longer.
This trial tests a new drug, ALK201, in people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and can shrink tumors.
This trial tests a new drug called ALK202 for people with advanced solid tumors that have not responded to other treatments. The study aims to see if the drug is safe and to find the best dose.
This trial tests a combination of two experimental drugs (LB1410 and LB4330) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments or where no standard treatment exists. It aims to see if this combination can shrink tumors or slow their growth.
Hear when a new Advanced Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.